Professor, Internal Medicine, University of Michigan Medical School
Oncology
Dr. Gregory P. Kalemkerian, MD
|
|
Give Review
Gregory Kalemkerian is an expert in the field of Oncology. He graduated from Northwestern University Feinberg School of Medicine. Northwestern University Feinberg School of Medicine has a rank of 19 in research and a 29 in primary care He received 4 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification" and "Whos Who in Medicine and Healthcare". Gregory Kalemkerian is a published doctor. He has 89 papers published. The most current publication "Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines." Gregory Kalemkerian accepts all Medicare patients.
Publications
- A statistical evaluation of dose expansion cohorts in phase I clinical trials.
- Advances in pharmacotherapy of small cell lung Cancer.
- KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma.
- Chemotherapy for small-cell lung Cancer.
- Randomized clinical trial of a brief and extensive dyadic intervention for advanced Cancer patients and their family caregivers.
- A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung Cancer.
- Notch pathway activity identifies cells with Cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma.
- Smoking status and survival in the national comprehensive Cancer network non-small cell lung Cancer cohort.
- Modern staging of small cell lung Cancer.
- The Application of Molecular Diagnostic Studies Interrogating EGFR and KRAS Mutations to Stained Cytologic Smears of Lung Carcinoma.
- Pulmonary Neuroendocrine carcinomas: progress and pitfalls.
- Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer.
- Advances in the treatment of small-cell lung Cancer.
- Semiquantification and classification of local pulmonary function by V/Q single photon emission computed tomography in patients with non-small cell lung Cancer: potent...
- Optimal anatomic coverage for CT in staging lung Cancer: Lessons from PET-CT correlation.
- Compassionate honesty.
- Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.
- Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung Cancer.
- An embryonic stem cell-like signature identifies poorly differentiated Lung adenocarcinoma but not squamous cell carcinoma.
- Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung Cancer: a combined analysis from B...
- Time to treatment in patients with stage III non-small cell lung Cancer.
- NCCN task force: clinical utility of PET in a variety of tumor types.
- The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung Cancer.
- Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung Cancer.
- Phase II study of celecoxib and docetaxel in non-small cell lung Cancer (NSCLC) patients with progression after platinum-based therapy.
- Progress and pitfalls in small-cell lung Cancer.
- Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung Cancer.
- Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
- Lung Cancer: beyond the guidelines.
- Long-term survival in paraneoplastic opsoclonus-myoclonus syndrome associated with small cell lung Cancer.
- Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
- Guidelines are never enough: a commentary on "when guidelines are not enough".
- Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung Cancer.
- Palliative chemotherapy for non-small cell lung Cancer: a measured dose of reality.
- Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung Cancer (NSCLC): predictors for radiation pneumonitis and fibrosis.
- Differentiation between carcinoid and sarcoid with F-18 FDG PET and In-111 pentetreotide.
- High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung Cancer: long-term results of a radia...
- False-positive findings with positron emission tomography in the staging of non-small-cell lung Cancer.
- Is collusion necessary? A commentary on necessary collusion.
- Lung Cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database.
- Run for your life: the reaction of some professionals to a person with Cancer.
- "But doctor, what have I got to lose...?".
- A positron-emitting internal marker for identification of normal tissue by positron emission tomography: phantom studies and validation in patients.
- Racial differences in lung Cancer.
- Unusual presentations of lung cancer: Case 2. Adrenal insufficiency as the initial manifestation of non-small-cell lung cancer.
- Unusual presentations of lung Cancer: Case 1. Diabetes insipidus as the initial manifestation of non-small-cell lung Cancer.
- Images in clinical medicine. Osteoporosis circumscripta.
- Growth inhibition and induction of apoptosis by fenretinide in small-cell lung Cancer cell lines.
- A phase II study of weekly alternating chemotherapy in extensive-stage small cell lung Cancer.
- Impact of race in lung Cancer: analysis of temporal trends from a surveillance, epidemiology, and end results database.
- "But doctor, what have I got to lose...?".
- Biology of lung Cancer.
- All-trans-retinoic acid alters myc gene expression and inhibits in vitro progression in small cell lung Cancer.
- Effect of v-rasH on sensitivity of NCI-H82 human small cell lung Cancer cells to cisplatin, etoposide, and camptothecin.
- Mechanism of all-trans-retinoic acid-mediated L-myc gene regulation in small cell lung Cancer.
- Tumor lysis syndrome in small cell carcinoma and other solid Tumors.
- Loss of heterozygosity on the long arm of human chromosome 7 in sporadic renal cell carcinomas.
- Induction of gastrin releasing peptide by all-trans retinoic acid in small cell lung Cancer cells.
- Lung Cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database.
- Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung Cancer cell lines.
- Inhibition of tumor cell growth by p21WAF1 adenoviral gene transfer in lung Cancer.
- A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell Lung carcinoma: an Eastern Cooperative Oncology Gr...
- Induction of apoptosis by a short-chain neuropeptide analog in small cell lung Cancer.
- Phase II study of hyperfractionated radiotherapy and concurrent weekly alternating chemotherapy in limited-stage small cell lung Cancer.
- Activity of 9-cis-retinoic acid and receptor-selective retinoids in small cell lung Cancer cell lines.
- Activity of fenretinide plus chemotherapeutic agents in small-cell lung Cancer cell lines.
- Retinoic acid-mediated growth inhibition of small cell lung Cancer cells is associated with reduced myc and increased p27Kip1 expression.
- Activity of dolastatin 10 against small-cell lung Cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification.
- Lung Cancer in patients < 50 years of age: the experience of an academic multidisciplinary program.
- Thrombospondin-1 expression and clinical implications in Malignant pleural mesothelioma.
- VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human Malignant mesothelioma tumours.
- Phase I trial of concurrent thoracic radiation and continuous infusion cisplatin and etoposide in stage III non-small cell lung Cancer.
- Etoposide-induced pulmonary toxicity.
- A phase II study of mitomycin C, etoposide, and cisplatin in advanced non-small cell lung Cancer.
- Phase II study of dolastatin-10 in patients with advanced non-small-cell lung Cancer.
- Non-Hodgkin's lymphoma: an Analysis of the Metropolitan Detroit SEER database.
- Therapeutic advances in small cell lung Cancer.
- Novel molecular and immunotherapeutic strategies for lung Cancer.
- 4-Hydroxyphenylretinamide in the chemoprevention of Cancer.
- Small cell lung Cancer clinical practice guidelines in oncology.
- Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung Cancer.
- Trastuzumab in the treatment of advanced non-small-cell lung Cancer: is there a role?
- Staging and imaging of small cell lung Cancer.
- Adjuvant therapy for non-small-cell lung Cancer.
- Lung Cancer growth curves based on CT imaging.
- Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung Cancer.
- The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung Cancer.
- Lung lesion doubling times: values and variability based on method of volume determination.
Schools
Northwestern Center Feinberg School of Medicine
Northwestern Meml Hospital
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Whos Who in Medicine and Healthcare
Education
-
Johns Hopkins University -
McGaw Medical Center of Northwestern University -
Northwestern University Feinberg School of Medicine
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1316023278 | |
| NPPES Provider LastName | KALEMKERIAN | |
| NPPES Provider FirstName | GREGORY | |
| NPPES Provider ZIPCode | 481095912 | |
| NPPES Provider State | MI | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 772.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 141.0 | |
| Percent Opioid Claims | 18.26 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1316023278 |
| Last Name Of The Provider | KALEMKERIAN |
| First Name Of The Provider | GREGORY |
| View All |
Similar Doctors
|
|
Dr. Rashmi Chugh, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey B. Smerage, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dean E. Brenner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathleen E. Bickel, MD |
|
|
Dr. Kunal C. Kadakia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer J. Griggs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander T. Pearson, MD
This Doctor is OpenDoctor Recommended.
|